Upstream Bio Inc (NASDAQ: UPB) has seen a decline in its stock price by -8.41 in relation to its previous close of 9.87. However, the company has experienced a 5.61% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-12 that – Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 –
Is It Worth Investing in Upstream Bio Inc (NASDAQ: UPB) Right Now?
There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for UPB is 19.15M, and at present, short sellers hold a 19.33% of that float. The average trading volume of UPB on March 19, 2025 was 312.61K shares.
UPB’s Market Performance
UPB’s stock has seen a 5.61% increase for the week, with a 18.95% rise in the past month and a -55.71% fall in the past quarter. The volatility ratio for the week is 9.33%, and the volatility levels for the past 30 days are at 10.49% for Upstream Bio Inc The simple moving average for the past 20 days is 7.06% for UPB’s stock, with a -44.95% simple moving average for the past 200 days.
Analysts’ Opinion of UPB
Piper Sandler gave a rating of “Overweight” to UPB, setting the target price at $75 in the report published on November 05th of the previous year.
UPB Trading at -7.85% from the 50-Day Moving Average
After a stumble in the market that brought UPB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.31% of loss for the given period.
Volatility was left at 10.49%, however, over the last 30 days, the volatility rate increased by 9.33%, as shares surge +7.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -44.54% lower at present.
During the last 5 trading sessions, UPB rose by +5.61%, in comparison to the 20-day moving average, which settled at $8.44. In addition, Upstream Bio Inc saw -45.01% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at UPB starting from Chimovits Erez, who purchase 825,000 shares at the price of $17.00 back on Oct 15 ’24. After this action, Chimovits Erez now owns 4,554,873 shares of Upstream Bio Inc, valued at $14,025,000 using the latest closing price.
ORBIMED ADVISORS LLC, the Director of Upstream Bio Inc, purchase 825,000 shares at $17.00 during a trade that took place back on Oct 15 ’24, which means that ORBIMED ADVISORS LLC is holding 4,554,873 shares at $14,025,000 based on the most recent closing price.
Stock Fundamentals for UPB
The liquidity ratio also appears to be rather interesting for investors as it stands at 44.63.
Conclusion
In summary, Upstream Bio Inc (UPB) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
